There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sensei Biotherapeutics (SNSE – Research Report), Abbott Labs (ABT – Research Report) and Personalis (PSNL – Research Report) with bullish sentiments.
Sensei Biotherapeutics (SNSE)
Citi analyst Samantha Semenkow maintained a Buy rating on Sensei Biotherapeutics yesterday and set a price target of $6.00. The company’s shares closed last Wednesday at $0.84.
According to TipRanks.com, Semenkow is a 5-star analyst with an average return of
Sensei Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.00, which is a 495.2% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
Abbott Labs (ABT)
In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Labs, with a price target of $133.00. The company’s shares closed last Wednesday at $120.05, close to its 52-week high of $120.15.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
Currently, the analyst consensus on Abbott Labs is a Strong Buy with an average price target of $126.54, which is a 5.9% upside from current levels. In a report issued on February 14, Stifel Nicolaus also maintained a Buy rating on the stock with a $125.00 price target.
Personalis (PSNL)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Personalis today and set a price target of $7.50. The company’s shares closed last Wednesday at $1.46.
According to TipRanks.com, Ramakanth is a 2-star analyst with an average return of
Personalis has an analyst consensus of Moderate Buy, with a price target consensus of $5.50, which is a 281.9% upside from current levels. In a report released today, Needham also reiterated a Buy rating on the stock with a $3.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SNSE:
- Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- Sensei Biotherapeutics Streamlines Board, Appoints Interim Chair
- Sensei Biotherapeutics Announces Board Member Resignation and Consultant Role
- Sensei Biotherapeutics to Present at Upcoming Conferences
- Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
